Praxis Precision Medicines, Inc. (PRAX) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
7.77
↑+121% vs avg
5yr avg: 3.51
30Y Low1.4·High7.6
ROE
↑
-45.8%
↓+52% vs avg
5yr avg: -95.8%
30Y Low-181%·High-38%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRAX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Praxis Precision Medicines, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8.8B | $6.6B | $1.4B | $147M | $110M | $836M | $492M | — | — |
| Enterprise Value | $8.4B | $6.3B | $1.2B | $68M | $52M | $702M | $197M | — | — |
| P/E Ratio → | -22.48 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 161.13 | 60.04 | — | — | — | — | — |
| P/B Ratio | 7.77 | 7.55 | 3.09 | 2.11 | 1.44 | 3.33 | 1.71 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRAX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 136.10 | 27.84 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
PRAX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have expanded from -5164.4% to -2340.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -45.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -1682.0% | -3445.8% | — | — | — | — | — |
| Operating Margin | — | — | -2340.3% | -5164.4% | — | — | — | — | — |
| Net Profit Margin | — | — | -2137.5% | -5037.9% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.8% | -45.8% | -71.0% | -169.1% | -130.9% | -62.1% | -37.7% | -129.6% | -180.7% |
| ROA | -42.7% | -42.7% | -64.0% | -121.4% | -104.9% | -56.1% | -35.2% | -105.2% | -133.8% |
| ROIC | -65.0% | -65.0% | -135.1% | -2140.7% | -239.9% | -232.3% | — | — | — |
| ROCE | -49.3% | -49.3% | -77.3% | -165.2% | -128.3% | -61.8% | -37.7% | -128.8% | -154.7% |
PRAX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $357M exceeds total debt of $110000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.02 | 0.00 | 0.04 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.41 | -0.48 | -1.13 | -0.76 | -0.54 | -1.03 | -1.08 | -1.22 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -206.89 |
Net cash position: cash ($357M) exceeds total debt ($110000)
PRAX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Praxis Precision Medicines, Inc.'s current ratio of 10.22x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.39x to 10.22x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.22 | 10.22 | 10.77 | 5.39 | 3.23 | 7.48 | 19.23 | 6.67 | 3.72 |
| Quick Ratio | 10.22 | 10.22 | 10.77 | 5.39 | 3.23 | 7.48 | 19.23 | 6.67 | 3.72 |
| Cash Ratio | 10.03 | 10.03 | 10.45 | 5.16 | 2.93 | 7.18 | 18.87 | 6.57 | 3.49 |
| Asset Turnover | — | — | 0.02 | 0.03 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
PRAX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Praxis Precision Medicines, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 6.1% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 6.1% | — | — |
| Shares Outstanding | — | $23M | $18M | $7M | $3M | $3M | $596677 | $101975 | $86509 |
Peer Comparison
Compare PRAX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRAXYou | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.6 | 26.3 | 36.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 NRIX | $2B | -6.1 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
 ARVN | $499M | -6.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 LGND | $5B | 42.8 | 68.3 | 107.4 | 97.5% | 17.6% | 13.5% | 3.4% | 5.6 |
 OVID | $297M | -9.4 | — | — | 95.9% | -585.2% | -17.5% | -33.9% | — |
 PTCT | $7B | 10.4 | 7.0 | 9.6 | 95.9% | 49.5% | — | — | 0.5 |
 KALA | $78M | -1.1 | — | — | — | — | -279.2% | — | — |
 ENOV | $1B | -1.0 | 9.3 | 61.6 | 59.8% | -0.8% | -58.4% | -0.4% | 5.0 |
 ILMN | $25B | 29.6 | 22.6 | 26.3 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $410M | -0.7 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PRAX — Frequently Asked Questions
Quick answers to the most common questions about buying PRAX stock.
What is Praxis Precision Medicines, Inc.'s P/E ratio?
Praxis Precision Medicines, Inc.'s current P/E ratio is -22.5x. This places it at the 50th percentile of its historical range.
What is Praxis Precision Medicines, Inc.'s ROE?
Praxis Precision Medicines, Inc.'s return on equity (ROE) is -45.8%. The historical average is -103.4%.
Is PRAX stock overvalued?
Based on historical data, Praxis Precision Medicines, Inc. is trading at a P/E of -22.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.